OTCMKTS:KHTRF - Knight Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.67
  • Forecasted Upside: 99.81 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.34
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Knight Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KHTRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KHTRF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.67
▲ +99.81% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is $8.67, with a high forecast of $10.50 and a low forecast of $7.75. The average price target represents a 99.81% upside from the last price of $4.34.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Knight Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/26/2021KCGBoost Price TargetOutperform$6.75 ➝ $7.75
i
4/26/2021Cannonball ResearchReiterated RatingBuy
i
4/26/2021Raymond JamesReiterated RatingOutperform
i
4/26/2021Knight EquityBoost Price TargetOutperform$6.75 ➝ $7.75
i
11/16/2020KCGLower Price TargetOutperform$8.25 ➝ $6.75
i
11/16/2020Knight EquityLower Price TargetOutperform$8.25 ➝ $6.75
i
8/13/2020Stifel NicolausInitiated CoverageBuy$10.50
i
Rating by Justin Keywood at Stifel Nicolaus
6/23/2020Stifel NicolausReiterated RatingBuy$10.50
i
Rating by Justin Keywood at Stifel Nicolaus
10/9/2019Raymond JamesSet Price TargetBuy$10.30
i
Rating by David Novak at Raymond James
4/5/2019Paradigm CapitalReiterated RatingHold
i
Rating by Rahul Sarugaser at Paradigm Capital
1/16/2019Raymond JamesReiterated RatingBuy
i
Rating by David Novak at Raymond James
2/22/2017Laurentian Bank of CanadaSet Price TargetHold$9.00
i
Rating by Joseph Walewicz at Laurentian Bank of Canada
(Data available from 6/14/2016 forward)
Knight Therapeutics logo
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $4.34
$4.34
$4.34

50 Day Range

MA: $4.35
$4.15
$4.57

52 Week Range

Now: $4.34
$3.95
$5.38

Volume

2 shs

Average Volume

24,715 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Knight Therapeutics?

The following equities research analysts have issued reports on Knight Therapeutics in the last twelve months: Cannonball Research, KCG Holdings, Inc., Knight Equity, Raymond James, and Stifel Nicolaus.
View the latest analyst ratings for KHTRF.

What is the current price target for Knight Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Knight Therapeutics in the last year. Their average twelve-month price target is $8.67, suggesting a possible upside of 99.8%. Stifel Nicolaus has the highest price target set, predicting KHTRF will reach $10.50 in the next twelve months. KCG Holdings, Inc. has the lowest price target set, forecasting a price of $7.75 for Knight Therapeutics in the next year.
View the latest price targets for KHTRF.

What is the current consensus analyst rating for Knight Therapeutics?

Knight Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KHTRF will outperform the market and that investors should add to their positions of Knight Therapeutics.
View the latest ratings for KHTRF.

What other companies compete with Knight Therapeutics?

How do I contact Knight Therapeutics' investor relations team?

The company's listed phone number is (514) 484-4483. The official website for Knight Therapeutics is www.gud-knight.com.